Compare TKC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKC | ACAD |
|---|---|---|
| Founded | 1993 | 1993 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.4B |
| IPO Year | 2000 | 2004 |
| Metric | TKC | ACAD |
|---|---|---|
| Price | $6.65 | $25.82 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 22 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.2M |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | ★ 2.39% | N/A |
| EPS Growth | N/A | ★ 98.53 |
| EPS | 0.11 | ★ 1.54 |
| Revenue | ★ $4,451,876,110.00 | $1,047,118,000.00 |
| Revenue This Year | $43.64 | $15.16 |
| Revenue Next Year | $28.36 | $11.79 |
| P/E Ratio | $24.98 | ★ $17.00 |
| Revenue Growth | N/A | ★ 12.69 |
| 52 Week Low | $5.35 | $13.40 |
| 52 Week High | $7.63 | $28.35 |
| Indicator | TKC | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 78.80 | 43.84 |
| Support Level | $6.51 | $25.25 |
| Resistance Level | $6.67 | $27.22 |
| Average True Range (ATR) | 0.10 | 0.95 |
| MACD | 0.10 | -0.13 |
| Stochastic Oscillator | 98.14 | 21.87 |
Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes high-quality mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Turkcell International, and Techfin. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.